Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 28, 2015 11:14 AM ET


Company Overview of NPS Pharmaceuticals, Inc.

Company Overview

NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support in the United States; and Revestive for the treatment of adult patients with SBS in the European Union. Its products also include Gattex/Revestive in pediatric SBS, which has completed an open-label 4-cohort study; Natpara, a bioengineered replica of human parathyroid hormone to control hypocalcemia in patients with hypoparathyroidism; and Natpar to treat hypoparathyroidism, as well as NPSP795, a calcilytic agent,...

550 Hills Drive

3rd Floor

Bedminster, NJ 07921

United States

Founded in 1986

365 Employees



Key Executives for NPS Pharmaceuticals, Inc.

Compensation as of Fiscal Year 2015.

NPS Pharmaceuticals, Inc. Key Developments

NPS Pharmaceuticals, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015

NPS Pharmaceuticals, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: May-26-2015, Francois Nader. May-27-2015, Francois Nader.

NPS Pharmaceuticals Announces Board Changes

NPS Pharmaceuticals, Inc. announced that In accordance with the terms of the Merger Agreement with Shire Pharmaceutical Holdings Ireland Limited and Knight Newco 2, Inc. (Purchaser), the directors of Purchaser immediately prior to the Effective Time became the directors of the Surviving Corporation. Accordingly, each of Francois Nader, Peter G. Tombros, Michael W. Bonney, Colin Broom, Georges Gemayel, Pedro Granadillo, James G. Groninger, Pierre Legault and Rachel R. Selisker ceased serving as members of the NPS Pharmaceuticals, Inc.'s board of directors as of the Effective Time. In addition, immediately following the Effective Time, all of the officers of the company immediately prior to the Effective Time were removed and were replaced by the officers of Purchaser.

NPS Pharmaceuticals, Inc.(NasdaqGM:NPSP) dropped from NASDAQ Composite Index

NPS Pharmaceuticals, Inc. will be removed from NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
MEDgenesis Inc. United States
Upstate USA, Inc. United States
Adlyfe Inc. United States
PAPGENE, INC. United States
Functional Genetics, Inc. United States

Recent Private Companies Transactions

January 11, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at